WebApr 6, 2024 · Company. Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and … WebNov 30, 2024 · PDUFA Target Action Date Set for November 30, 2024. FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has …
China Universal Asset Management Co. Ltd. Lowers Holdings in ...
WebStock analysis for Cytokinetics Inc (CYTK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. WebMar 6, 2024 · PRESENTATIONS Cytokinetics, Inc. INVESTORS & MEDIA PRESENTATIONS NASDAQ : CYTK $35.19 +0.98 (+2.86%) Mar 31 2024 4:00 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART SHAREHOLDER TOOLS Print Page Email Alerts IR/Media Contacts dr fields boston legal
Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks - Yahoo …
WebMar 16, 2024 · Cytokinetics, Incorporated Common Stock (CYTK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. WebApr 13, 2024 · China Universal Asset Management Co. Ltd. trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 96.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.The institutional investor owned 961 shares of the biopharmaceutical … WebOct 27, 2024 · Blum acknowledges some CYTK stock investors are watching for a possible Cytokinetics buyout after Bristol Myers spent north of $13 billion to acquire MyoKardia … enkore active software